You are here:Home-Research Areas-Infection-Parasite Infection

Request The Product List ofParasite Infection Parasite Infection

Cat. No. Product Name CAS No. Information
PC-61691

MMV390048

1314883-11-8

MMV390048 is a novel potent Plasmodium PI4K inhibitor with IC50 of 28 nM against intraerythrocytic life cycle stages of P. falciparum (NF54 drug-sensitive strain); blocks all life cycle stages of the malaria parasite, exhibits full chemoprotection, delays relapse in a Plasmodium cynomolgi monkey model.

Parasite Infection

Phase 2 Clinical

PC-61378

Ganaplacide

1261113-96-5

Ganaplacide (KAF156, GNF-156) is a novel antimalarial clinical candidate that shows blood schizonticidal activity with IC50 of 6-17.4 nM against P falciparum drug-sensitive and drug-resistant strains; demonstrates potent therapeutic activity in mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively; KAF156 is completely protective as a single oral dose of 10 mg/kg in sporozoite challenge mouse model; shows the potential to treat, prevent, and block the transmission of malaria.

Parasite Infection

Phase 2 Clinical

PC-60316

SCYX-7158

1266084-51-8

SCYX-7158 (AN-5568, Acoziborole) is an orally-active, CNS permeable benzoxaborole antiprotozoal agent; is active in vitro against relevant strains of Trypanosoma brucei, including T. b. rhodesiense and T. b. gambiense; is efficacious in both stage 1 and stage 2 murine HAT models and has good physicochemical and ADMET properties for the treatment of stage 2 human African trypanosomiasis.

Parasite Infection

Phase 3 Clinical

PC-46931

Suramin sodium salt

129-46-4

Suramin sodium salt (BAY-205, NF-060) is an antitrypansomal drug that also possesses antitumor activity; inhibits CRL (Cullin-RING E3 ubiquitin ligases) activity by disrupting its ability to recruit Cdc34; induces accumulation of CRL substrates; also inhibits multiple viruses (ZIKVs, EV71).

Parasite Infection

Approved

PC-63382

Tafenoquine succinate

106635-86-3 Tafenoquine succinate (SB-252263, Tafenoquine, WR 238605) is a long-acting, orally active anti-malarial agent to prevent malaria that is holoendemic for Plasmodium falciparum.

Parasite Infection

Phase 3 Clinical

PC-63381

Tafenoquine

106635-80-7 Tafenoquine (SB-252263, Tafenoquine, WR 238605) is a long-acting, orally active anti-malarial agent to prevent malaria that is holoendemic for Plasmodium falciparum.

Parasite Infection

Phase 3 Clinical

PC-63378

Cipargamin

1193314-23-6 Cipargamin (KAE609, NITD609) is a fast-acting, potent antimalarial agent that inhibits blood-stage activity in vitro against a panel of culture-adapted P. falciparum strains with IC50 of 0.5-1.4 nM; inhibits the early and late development of Plasmodium falciparum gametocytes in vitro in a dose-dependent fashion over a range of 5 to 500 nM; also is a very effective drug in reducing transmission to the Anopheles stephensi mosquito vector; shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in rodent malaria model.

Parasite Infection

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com